Blood Parameters in Lymphoma Diagnosis and Monitoring

Essential Laboratory Parameters

Elevated LDH is a characteristic finding in non-Hodgkin's lymphomas and serves as an early marker of occult lymphoma, even before clinical manifestations, according to the American College of Physicians 1
Increased beta-2 microglobulin is an important prognostic marker in follicular lymphoma and should be measured at diagnosis, as recommended by the American Society of Hematology 2, 3
Elevated uric acid levels may occur due to increased cell turnover, as noted by the National Comprehensive Cancer Network 4, 5

The Follicular Lymphoma International Prognostic Index (FLIPI) includes hemoglobin and elevated LDH as key prognostic factors, according to the European Society for Medical Oncology 6
FLIPI 2 incorporates beta-2 microglobulin, hemoglobin levels, and bone marrow involvement, as recommended by the American Society of Hematology 2, 3
PRIMA-PI risk stratification uses beta-2 microglobulin levels and bone marrow involvement, as noted by the European Society for Medical Oncology 6

Complete blood count with differential to assess for cytopenias, leukocytosis, or abnormal cells is essential, as recommended by the National Comprehensive Cancer Network 4, 6
LDH measurement is mandatory in the initial workup, according to the National Comprehensive Cancer Network 4, 5
Beta-2 microglobulin determination is necessary, as recommended by the American Society of Hematology 2, 6
Immunoglobulin levels should be measured as part of initial assessment, as noted by the European Society for Medical Oncology 6, 7

Serial LDH measurements are useful for monitoring disease activity and response to therapy, according to the American College of Physicians 1
Normalization of blood parameters often correlates with treatment response, as noted by the National Comprehensive Cancer Network 4, 5

Laboratory test values may differ substantially between testing facilities and among populations, with significant racial/ethnic differences in normal ranges for many parameters, as noted by the American Association for Cancer Research 8
Bone marrow involvement assessment may be falsely negative if the biopsy is inadequate in size or from a non-involved site, as recommended by the American Society of Hematology 2, 3